NCT00783003 - A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2008

Primary Completion Date

February 6, 2009

Study Completion Date

February 6, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705 and GW642444

Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.

DRUG

GW642444

Inhaled Long acting Beta 2 agonist (LABA)

DRUG

GSK233705

Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.

DRUG

Placebo

Matching placebo.

Trial Locations (1)

E1 4NL

GSK Investigational Site, Stepney Green